The purpose of this Medical Access Program (also referred to as an Expanded AccessProgram in the USA) is to provide access to Dato-DXd for eligible patients withpreviously treated advanced or metastatic EGFR mutated non-small cell lung cancer (NSCLC)who, in their treating physician's opinion, have an unmet clinical need, are unlikely toobtain optimal benefit from currently approved and commercially available drugs, and whocannot enter a suitable clinical trial.